Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10102
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome Alachkar, Houda , Santhanam, Ramasamy , Maharry, Kati ... - - J. Clin. Invest - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-9621
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147
Exercise and Dietary Change after Diagnosis and Cancer-related Symptoms in Long-term Survivors of Breast Cancer: CALGB 79804 Alfano, Catherine M. , Day, Jeannette M. , Katz, Mira L. ... - - Psychooncology - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-70804
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma Ansell, Stephen M. , Novak, Anne J. , Ziesmer, Steven ... - - Am J Hematol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - NCCTG-98-78-51
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305 Armer, Jane M , Liu, Heshan , Oliveri, Jill , Seisler, Drew , tbd ... - ASCO CSS - J. Clin. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - CALGB-70305
Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors Arnold, Kristen , Andridge, Rebecca , Logan, Amanda , Yee, Lisa ... - EB - FASEB J - 2015 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - NCT01478477
Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA Atherton, Pamela J. , Halyard, Michele Y. , Sloan, Jeff A. ... - - Support Care Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Symptom Inter - N00CA
Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance]) Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) Augert, Arnaud , Zhang, Qing , Bates, Breanna , Cui, Min ... - - J Thorac Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Sequencing - CALGB-151111
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720 , CALGB-9760
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Adiponectin: A novel biomarker for cancer- related fatigue?; NCCTG study N07C2 (Alliance) Barton, D. , Liu, H. , Tan, A. , Sloan, J. ... - MASCC / ISOO - Support Care Cancer - 2013 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N07C2
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) Barton, Debra L. , Shuster, Lynne T. , Dockter, Travis ... - - Support Care Cancer - 2018 Manuscript - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance) Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML) Becker, H. , Marcucci, G. , Maharry, K. , Margeson, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720
CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - - Haematologica - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 Becker, Heiko , Maharry, Kati , Mrózek, Krzysztof , Volinia, Stefano ... - - Leukemia - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Maharry, Kati , Radmacher, Michael D. ... - - Haematologica - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-9720
Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103) Beumer, Jan H. , Owzar, Kouros , Lewis, Lionel D. , Jiang, Chen ... - - Cancer Chemother. Pharmacol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - PPP - C19808 , CALGB-100103 , CALGB-10503
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) Bhatnagar, B , Blachly, JS , Kohlschmidt, J , Eisfeld, A-K ... - - Leukemia - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , C8525 , CALGB-10102 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-11002 , CALGB-19808 , CALGB-8923 , CALGB-9120 , CALGB-9222 , CALGB-9621 , CALGB-9720
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Nicolet, Deedra ... - - Br. J. Haematol. - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-9222 , CALGB-9621 , CALGB-9720
Perioperative Patient Reported Outcomes Predict Serious Postoperative Complications: A Secondary Analysis of the COST Trial Bingener, Juliane , Sloan, Jeff A. , Novotny, Paul J. ... - - J. Gastrointest. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-93-46-53
Cognitive Function and Discontinuation of Adjuvant Hormonal Therapy in Older Breast Cancer Survivors: CALGB 369901 (Alliance) Bluethmann, Shirley M. , Alfano, Catherine M. , Clapp, Jonathan D. ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235 Bogart, Jeffrey A. , Watson, Dorothy , McClay, Edward F. ... - - Lung Cancer - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9235
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Boughey, Judy C. , Ballman, Karla V. , Hunt, Kelly K. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071 Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - Ann. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902 Boylan, Alice M. , Wang, Xiaofei F , Ko, Richard , Watson, Patricia M ... - - J. Thorac. Cardiovasc. Surg. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159902
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer Brambilla, Elisabeth , Le Teuff, Gwénaël , Marguet, Sophie ... - - J. Clin. Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9633
Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1 Brown, L. C. , Atherton, P. J. , Neben-Wittich, M. A. , Wender, D. B. ... - - Support Care Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - N09C1
Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041) Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041
Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - - JAMA Oncol - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Campbell, Jeffrey I. , Yau, Christina , Krass, Polina , Moore, Dan ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context Campbell, Michael J. , Wolf, Denise , Mukhtar, Rita A. ... - - PLoS ONE - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL Chen, S. S. , Claus, R. , Lucas, D. M. , Yu, L. , Qian, J. ... - - Blood - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C20305 , C9712
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Cheng, H , Ballman, K , Vassilakopoulou, M , Dueck, A C ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0441 , NCCTG-N0441
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GU - A031203
Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial Churilla, Thomas M. , Ballman, Karla V. , Brown, Paul D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0574
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657) Clark, Amy S , Chen, Jinbo , Kapoor, Shiv , Friedman, Claire ... - - Cancer Med - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia Claus, R. , Lucas, D. M. , Stilgenbauer, S. , Ruppert, A. S. , Yu, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9712
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Crozier, J. A. , Moreno-Aspitia, A. , Ballman, K. V. , Dueck, A. C. ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Cureton, Elizabeth L. , Yau, Christina , Alvarado, Michael D. ... - - Ann. Surg. Oncol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Cushman, Stephanie M. , Jiang, Chen , Hatch, Ace J. , Shterev, Ivo ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80203
The Feasibility of Radiotherapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Cuttino, Laurie , McCall, Linda , Kubicky, C , Ballman, Karla ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019 Abstract - Secondary Endpoint - Primary Analysis - Prevention - Z11102
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GU - CALGB-9682
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance) DeBoer, Rebecca , Mulkey, Flora , Koval, Gregory , Wetzler, Meir ... - EHA - Haematologica - 2014 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001 , CALGB-9665
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657) Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657) Demichele, A. , Yau, C. , Zhu, J. , Wuhfkuhle, J. , Lenburg, M. E. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. DiGiovanna, Michael P , Stern, David F , Edgerton, Susan ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C8541
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - N1048
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer) Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031
Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance) Durá-Ferrandis, Estrella , Mandelblatt, Jeanne S. , Clapp, Jonathan ... - - Psychooncology - 2017 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Older Adult - CALGB-369901
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304 Edelman, M. J. , Hodgson, L. D. , Wang, X. , Christenson, R. H. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304 Edelman, Martin J. , Hodgson, Lydia , Rosenblatt, Paula Y. ... - - J Thorac Oncol - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150304
Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304 Edelman, Martin J. , Hodgson, Lydia , Wang, Xiaofei ... - - J Thorac Oncol - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304 , CALGB-30203
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ALTTO
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2 Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - - Leukemia - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Schwind, Sebastian ... - - Leukemia - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665
Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665
MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia Eisfeld, Ann-Kathrin , Marcucci, Guido , Liyanarachchi, Sandya ... - - Proc. Natl. Acad. Sci. U.S.A - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9665
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia Eisfeld, Ann-Kathrin , Marcucci, Guido , Maharry, Kati ... - - Blood - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9665
Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - - Cancer Research - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy ... - - J. Clin. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657 Esserman, L. J. , Berry, D. A. , Demichele, A. , Carey, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012 , ACRIN-6657
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657) Esserman, L. J. , Perou, C. M. , Cheang, M. , Demichele, A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Esserman, Laura J. , Berry, Donald A. , Cheang, Maggie C. U. ... - - Breast Cancer Res. Treat - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study Farmer, Roger W. , McCall, Linda , Civantos, Francisco J. ... - - Otolaryngol Head Neck Surg - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901 Faul, Leigh Anne , Luta, Gheorghe , Sheppard, Vanessa ... - - J Cancer Surviv - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study Fernando, H. C. , Landreneau, R. J. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 91st Annual Meeting - 2011 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Analysis of longitudinal quality of life data in high-risk operable patients with lung cancer: Results from ACOSOG Z4032 (Alliance) a multicenter randomized trial Fernando, Hiran C , Landreneau, Rodney J , Mandrekar, Sumithra J ... - - J. Thorac. Cardiovasc. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - ACOSOG-Z4032
Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710 Feusner, J. , Gregory, J. , Moser, B. K. , Hars, V. , Powell, B. L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710
Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set Fibla, Juan J. , Cassivi, Stephen D. , Brunelli, Alessandro ... - - Lung Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial Fleshman, J , Branda, ME , Sargent, DJ , Boller, AM , George, VV ... - - Ann. Surg. - 2019 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6051
Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - N994C
Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Mandrekar, Sumithra J. , Schild, Steven E. ... - - Cancer - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer Francis, Prue , Fleming, Gini , Regan, Meredith , Pagani, Olivia ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907 Freedman, R. , Pitcher, B. , Keating, N. , Barry, W. , Ballman, K. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907 Freedman, Rachel A. , Pitcher, Brandelyn , Keating, Nancy L. ... - - Breast Cancer Res. Treat. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907 , CALGB-361002
Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-98-46-54
Dietary and lifestyle determinants of colon cancer recurrence and survival Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - GI - C89803
KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803 Fuchs, C. S. , Ogino, S. , Meyerhardt, J. A. , Irahara, N. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) Fuchs, M. A. , Yuan, C. , Sato, K. , Niedzwiecki, D. , Ye, X. ... - - Ann. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) Fuchs, Michael A. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - PLoS ONE - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50403
Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance] Gajra, Ajeet , McCall, Linda , Muss, Hyman B. , Cohen, Harvey J. ... - SABCS - Cancer Res. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907
Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R. J. , Chan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Expression and prognostic impact of lncRNAs in acute myeloid leukemia Garzon, Ramiro , Volinia, Stefano , Papaioannou, Dimitrios ... - - Proc. Natl. Acad. Sci. U.S.A - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202
Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial George, Daniel J. , Hessel, Colin , Halabi, Susan ... - - Oncologist - 2019 Manuscript - Secondary Endpoint - Primary Analysis - GU - A031203
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance) George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-90206
Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. W. ... - ASA - American Surgical Association 130th Annual Meeting - 2010 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Giuliano, Armando E. , Ballman, Karla V. , McCall, Linda ... - - JAMA - 2017 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial Giuliano, Armando E. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. - 2016 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Ten-Year Survival Results of ACOSOG Z0011 (Alliance) Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011
Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - - Ann. Surg. - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel, Ajay , Nagasaka, Takeshi , Arnold, Christian N , Inoue, Toru ... - - Gastroenterology - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-9865
Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. Goetz, M. P. , Moyer, A. M. , Weinshilboum, R. M. , Suman, V. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Tamoxifen Pharmacogenetics of CYP2D6, CYP2C19, and SULTIA1: Long Term Follow-up of the North Central Cancer Treatment Group 89-30-52 Adjuvant Trial. Goetz, M. , Suman, V. , Ames, M. , Black, J. , Safgren, S. , Kuffel, M. ... - - Cancer Res. - 2009 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - PPP - NCCTG-89-30-52
CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of tamoxifen resistance Goetz, Matthew P. , Suman, Vera J. , Couch, Fergus J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz, Matthew P , Knox, Stacey K , Suman, Vera J , Rae, James M ... - - Breast Cancer Res. Treat. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance). Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald A. ... - ASA - - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance) Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603
Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Golshan, Mehra , Cirrincione, Constance T. , Sikov, William M. ... - - Ann. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603
Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL Gomez, R. , Zakhireh, J. , Moore, D. , Demichelle, A. , Przewoznik, J. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80803
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials Gorlia, Thierry , Wu, Wenting , Wang, Meihua , Baumert, Brigitta G. ... - - Neuro-oncology - 2013 Manuscript - Secondary Endpoint - Comprehensive Analysis - Neuro-Onc - NCCTG-86-72-51
Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633 Graziano, S. L. , Gu, L. , Wang, X. , Tatum, A. , Vollmer, R. T. ... - - J Thorac Oncol - 2007 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159802 , CALGB-9633
Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633 Graziano, Stephen L. , Gu, Lin , Wang, Xiaofei , Tatum, Arthur H. ... - - J Thorac Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9633
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Guercio, Brendan J. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Prevention - C89803
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary Endpoint - Preliminary Analysis - GI - CALGB-80405
Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance) Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia Hackanson, B. , Bennett, K. L. , Brena, R. M. , Jiang, J. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Hackanson, Björn , Bennett, Kristi L , Brena, Romulo M ... - - Cancer Res. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665
Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study. Halyard, M. Y. , Dueck, A. C. , Pisansky, T. M. , Mclaughlin, S. A. ... - SABCS - Cancer Res. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-89-20-52
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 Harris, Lyndsay N. , Broadwater, Gloria , Abu-Khalaf, Maysa ... - - J. Clin. Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C8541 , CALGB-150013
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer Hatzis, Christos , Pusztai, Lajos , Valero, Vicente ... - - JAMA - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML Havelange, Violaine , Ranganathan, Parvathi , Geyer, Susan ... - - Blood - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , C9720 , CALGB-10201 , CALGB-8923 , CALGB-9420
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Heinrich, Michael C. , Owzar, Kouros , Corless, Christopher L. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-150105
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 Heun, James M. , Grothey, Axel , Branda, Megan E. ... - - Oncologist - 2011 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia Hickey, Christopher J. , Schwind, Sebastian , Radomska, Hanna S. ... - - Blood - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9621 , CALGB-19808
Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without+/- lapatinib (L) for HER2-positive breast cancer Hoadley, Katherine A. , Barry, William T. , Pitcher, Brandelyn N. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance) Hoadley, Katherine A. , Hyslop, Terry , Fan, Cheng , Berry, Donald A. ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40603
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50103
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary Endpoint - Comprehensive Analysis - GI - ACCENT , CALGB-89803
Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial Hunt, Kelly K. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC) Hunt, Kelly K. , Suman, Vera J. , Meric-Bernstam, Funda ... - SSO - Ann Surg Oncol - 2019 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Functional Decline and Resilience among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer Hurria, Arti , Soto-Perez-de-Celis, Enrique , Allred, Jacob B. ... - - J Am Geriatr Soc - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-361007 , CALGB-49907
MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007 Hylton, N. M. , Blume, J. , Gastonis, C. , Gomez, R. , Bernreuter, W. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACRIN-6657 , CALGB-150007
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL Hylton, Nola M. , Gatsonis, Constantine A. , Rosen, Mark A. ... - - Radiology - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603 Iglesia, Michael D. , Vincent, Benjamin G. , Serody, Jonathan S. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603
Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303 Innocenti, F. , Owzar, K. , Cox, N. J. , Evans, P. , Kubo, M. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303
An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance) Innocenti, Federico , Jiang, Chen , Sibley, Alexander B. ... - - Pharmacogenet. Genomics - 2019 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303
Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance) Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Innocenti, Federico , Owzar, Kouros , Cox, Nancy L. , Evans, Patrick ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303 , C151006
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ECC - Eur J Cancer - 2015 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80405
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 Jackson, N. A. , Fuchs, C. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Radiation field design on the ACOSOG Z0011 trial Jagsi, R. , Ballman, K. , Chadha, M. , Moni, J. , Laurie, F. ... - SABCS - Cancer Res. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial Jagsi, Reshma , Chadha, Manjeet , Moni, Janaki , Ballman, Karla ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406 Janne, P. A. , Wang, X. , Socinski, M. A. , Crawford, J. , Gu, L. ... - - J Thorac Oncol - 2011 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-30406
Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor Induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)1 Jatoi, Aminah , Dakhil, Shaker R. , Sloan, Jeff A. , Kugler, John W. ... - - Support Care Cancer - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Symptom Inter - N03CB
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 Jatoi, Aminah , Green, Erin M. , Rowland, Jr. Kendrith M. ... - - Oncology - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222 Jatoi, Aminah , Hillman, Shauna L , Ziegler, Katie L Allen ... - - Cancer Manag Res - 2009 Manuscript - Secondary Endpoint - Comprehensive Analysis - Respiratory - N0222 , N9921
Social Support and Its Implications in Older, Early-Stage Breast Cancer Patients in CALGB 49907 (Alliance A171301) Jatoi, Aminah , Muss, Hyman , Allred, Jake B. , Cohen, Harvey J. ... - - Psychooncology - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907 , A171301
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. Jatoi, Aminah , Nguyen, Phuong L , Foster, Nathan , Sun, David ... - - J Support Oncol - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0242
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803 / ALLIANCE Jeon, Justin , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Prevention - CALGB-89803
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary Endpoint - Preliminary Analysis - GI - N044E
Cancer Surveillance Behaviors and Psychosocial Factors Among Long-Term Survivors of Breast Cancer Katz, Mira L. , Donohue, Kathleen A. , Alfano, Catherine M. ... - - Cancer - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-79804
CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/-T in HER-2(+) and (-) metastatic breast cancer (MBC) Kaufman, P. A. , Broadwater, G. , Lezon-Geyda, K. A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C150002
Impact of Sublobar Resection on Pulmonary Function: Long-term Results from ACOSOG Z4032 (Alliance) Kent, Michael S. , Mandrekar, Sumithra J. , Landreneau, Rodney ... - - Ann. Thorac. Surg. - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia Khandanpour, C. , Thiede, C. , Valk, P. J. , Sharif-Askari, E. ... - - Blood - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C8461
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) Kim, G. P. , Marsoni, S. , Monges, G. , Allegra, C. J. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - N994C
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC) Klepin, H. D. , Pitcher, B. , Ballman, K. V. , Kimmick, G. G. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-70103 , CALGB-49907
Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance) Klepin, Heidi D. , Pitcher, Brandelyn N. , Ballman, Karla V. ... - - J Oncol Pract - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907 , CALGB-361004
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831 Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238 Kohman, L. J. , Watson, D. M. , Herndon, J. E., 2nd , Eves, N. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-140803 , CALGB-9238
Quality of life of early stage breast cancer patients 65 years old or older randomized to standard chemotherapy or capecitabine (CALGB 49907) Kornblith, A. B. , Archer, L. E. , Lan, L. , Kimmick, G. G. ... - - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907
Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907 Kornblith, Alice B. , Lan, Lan , Archer, Laura , Partridge, Ann ... - - J Clin Oncol - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - C70103 , CALGB-49907
Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone? Kostakoglu, L. , Schoder, H. , Hall, N. C. , Straus, D. J. ... - ASH - ASH Annual Meeting Abstracts - 2011 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50203
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Kostakoglu, Lale , Schöder, Heiko , Johnson, Jeffrey L ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50203
A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance). Kottschade, Lisa , Allred, Jacob , Rumila, K. , Markovic, Svetomir ... - SMR - - 2017 Abstract - Secondary Endpoint - Primary Analysis - Experimental - N0879
Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001 Koval, G. , Wetzler, M. , Watson, D. , Owzar, K. , Bloomfield, C. D. ... - - Blood - 2011 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001
Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Kozower, Benjamin D , Meyers, Bryan F , Reed, Carolyn E ... - - Ann. Thorac. Surg. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0050
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. Kratzke, Robert A , Wang, Xiaofei , Wong, Long , Kratzke, Marian G ... - - J Thorac Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159904
Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab Krop, Ian E. , Hillman, David , Polley, Mei , Tanioka, Maki ... - SABCS - Cancer Res - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia Kühnl, Andrea , Kaiser, Martin , Neumann, Martin , Fransecky, Lars ... - - Leuk. Res. - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C20202 , C9621 , C8461
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-59804
Utilization of receptor targeted technetium Tc 99m Tilmanocept (lymphoseek injection) to identify and evaluate the pathological status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral squamous cell carcinoma: A preliminary performance evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360 study Lai, S. Y. , Agrawal, A. ... - SSO - Ann. Surg. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Generalizability of Trial Results to Elderly Medicare Patients with Advanced Solid Tumors (Alliance 70802) Lamont, Elizabeth B. , Schilsky, Richard L. , He, Yulei , Muss, Hyman ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-70802
Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802) Lamont, Elizabeth B. , Yu, Menggang , He, Yulei , Saltz, Leonard ... - - J Geriatr Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-70802
Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival Landis, M. , Yau, C. , Neumeister, V. , Rimm, D. , Esserman, L. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study Langer, C. , Maharry, K. S. , Mrozek, K. A. , Paschka, P. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-9621
High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study Langer, C. , Ruppert, A. S. , Radmacher, M. D. , Whitman, S. P. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Langer, Christian , Marcucci, Guido , Holland, Kelsi B. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Langer, Christian , Radmacher, Michael D. , Ruppert, Amy S. ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905) Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G. ... - - Clin Cancer Res - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9344 , CALGB-159905
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10603
Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071) Le-Petross, H. T. , Mccall, L. , Hunt, K. , Mittendorf, E. A. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Le-Petross, Huong T. , McCall, Linda M. , Hunt, Kelly K. ... - - AJR Am J Roentgenol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Comparison of results from three different density assessment methods on mammographic density (MD) in a screening patients receiving vitamin D (Vit D): Results of CALGB 70806 (Alliance) Le-Petross, Huong T. , Seisler, Drew K. , Kontos, Despina ... - RSNA - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Prevention - CALGB-70806
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial Lesurf, R. , Griffith, O. L. , Griffith, M. , Hundal, J. , Trani, L. ... - - Ann. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The genomics of response to neoadjuvant trastuzumab in HER2-positive breast cancer – results from the ACOSOG Z1041 (Alliance) trial Lesurf, Robert , Griffith, Malachi , Griffith, Obi , Watson, Mark A. ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer - results from the ACOSOG Z1041 (Alliance) trial Lesurf, Robert , Griffith, Obi , Griffith, Malachi , Trani, Lee ... - PCC - - 2016 Abstract - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance) Lewis, L. D. , Miller, A. A. , Owzar, K. , Bies, R. R. , Markova, S. ... - - Pharmacogenet Genomics - 2013 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-60805
DNMT3A mutations in acute myeloid leukemia Ley, T. J. , Ding, L. , Walter, M. J. , Mclellan, M. D. ... - - N. Engl. J. Med. - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C8461
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome Ley, T. J. , Mardis, E. R. , Ding, L. , Fulton, B. , Mclellan, M. D. ... - - Nature - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C8461
Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study Li, Daneng , Dickler, Maura N. , McCall, Linda M. , Hahn, Olwen M ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-40503
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study. Li, Daneng , McCall, Linda M. , Hahn, Olwen M , Hudis, Clifford A. ... - - Breast Cancer Res. Treat. - 2018 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-40503
RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657) Li, J. , Yau, C. , Campbell, M. , Park, J. W. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Association of Variants with Bevacizumab-Induced Hypertension Identified by Exome Sequencing CALGB-80405 (Alliance) Li, Megan , Mulkey, Flora , Jiang, Chen , Venook, Alan P. ... - ASCPT - - 2016 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL Li, Wen , Arasu, Vignesh , Newitt, David C. , Jones, Ella F. ... - - Tomography - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACRIN 6657 , CALGB-150007
Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (>65 years): CALGB/CTSU 49907 (CC) ancillary data study Lichtman, S. M. , Cirrincione, C. , Hurria, A. , Jatoi, A. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907 , A171201
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907 Lichtman, Stuart M. , Cirrincione, Constance T. , Hurria, Arti ... - - J. Clin. Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - A171201 , CALGB-49907
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) Ligibel, Jennifer A. , Cirrincione, Constance T. , Liu, Minetta ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - C9741 , CALGB-40902
Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance) Ligibel, LJ , Heubner, JA , Rugo, HS , Burstein, H , Toppmeyer, DL ... - SABCS - Cancer Res - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40502
Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening Lin, C. , Moore, D. , Demichele, A. , Ollila, D. W. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) Lin, Cheryl , Buxton, Meredith Becker , Moore, Dan , Krontiras, Helen ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007 , CALGB-150012
Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes Liotta, L. , Pierobon, M. , Wulfkuhle, J. , Laird, J. , Livasy, C. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer Lips, Esther H. , Mukhtar, Rita A. , Yau, Christina ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Liu, Hongtao , Johnson, Jeffrey L. , Koval, Greg , Malnassy, Greg ... - - Haematologica - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-59909
PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9741
Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial Liu, M.C. , Rack, B. , Dueck, A.C. , Hillman, D.W. , Campion, M.B. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel Liu, Minetta C. , Demetri, George D. , Berry, Donald A. ... - - Cancer Treat Rev - 2008 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - C9141
Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-driven Myeloid Leukemia Liu, Shujun , Wu, Lai-Chu , Pang, Jiuxia , Santhanam, Ramasamy ... - - Cancer Cell - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Liu, Ting Xi , Becker, Michael W , Jelinek, Jaroslav , Wu, Wen-Shu ... - - Nat. Med. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Liu, Y. , Starr, M. D. , Bulusu, A. , Pang, H. , Wong, N. S. ... - - Cancer Med - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80303
Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102) Lozanski, G. , Sanford, B. , Mrozek, K. , Edwards, C. , Pearson, R. ... - ASH - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10102 , CALGB-8461 , CALGB-9665 , CALGB-9862
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study Lozanski, Gerard , Ruppert, Amy S. , Heerema, Nyla A. ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9712 , CALGB-9665
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. Lucci, Anthony , McCall, Linda Mackie , Beitsch, Peter D ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors Luo, Jingqin , Liu, Shuzhen , Leung, Samuel , Gru, Alejandro A. ... - - J Mol Diagn - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 / NCCTG N063H (Alliance) Magbanua, Mark Jesus M. , Hendrix, Laura , Hyslop, Terry ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40502 , NCCTG-N063H
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response Magbanua, Mark Jesus M. , Wolf, Denise M. , Yau, Christina ... - - Breast Cancer Res - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), disease-free survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581 Mahmoud, N. N. , Lopatin, M. , Lee, M. , Clark-Langone, K. ... - - Eur. J. Cancer - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901 Mandelblatt, J. S. , Faul, L. A. , Luta, G. , Makgoeng, S. B. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB 369901 Mandelblatt, J. , Sheppard, V. , Hurria, A. , Kimmick, G. G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Frailty and Long-term Mortality Of Older Breast Cancer Patients: CALGB 369901 (Alliance) Mandelblatt, Jeanne S. , Cai, Ling , Luta, George , Kimmick, Gretchen ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance) Mandelblatt, Jeanne S. , Clapp, Jonathan D. , Luta, Gheorghe ... - ICCTF - Cancer - 2016 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB 49907 and 369901 Mandelblatt, Jeanne S. , Makgoeng, Solomon B. , Luta, Gheorghe ... - - J Geriatr Oncol - 2013 Manuscript - Secondary Endpoint - Comprehensive Analysis - Older Adult - CALGB-49907 , CALGB-369901
Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation Mandrekar, S. J. , Hillman, S. L. , Ziegler, K. L. Allen ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation Mandrekar, S. J. , Qi, Y. , Allen-Ziegler, K. , Hillman, S. L. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts) Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Paschka, P. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20202 , CALGB-9621
High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Vukosavljevic, T. ... - AACR - AACR Annual Meeting - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study Marcucci, G. , Maharry, K. S. , Wu, Y. , Radmacher, M. D. ... - - Haematologica - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study Marcucci, G. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20205 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10801
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients Marcucci, Guido , Maharry, Kati S. , Metzeler, Klaus H. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665 , CALGB-20202
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study Marcucci, Guido , Maharry, Kati , Radmacher, Michael D. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. Marcucci, Guido , Maharry, Kati , Whitman, Susan P ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20205 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Marcucci, Guido , Maharry, Kati , Wu, Yue-Zhong ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8421 , C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia Marcucci, Guido , Metzeler, Klaus H. , Schwind, Sebastian ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9621 , CALGB-19808
MicroRNA expression in cytogenetically normal acute myeloid leukemia. Marcucci, Guido , Radmacher, Michael D , Maharry, Kati ... - - N. Engl. J. Med. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score Marcucci, Guido , Yan, Pearlly , Maharry, Kati , Frankhouser, David ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-9420 , CALGB-9720 , CALGB-9621 , CALGB-19808
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Maurer, Matthew J. , Ghesquières, Hervé , Jais, Jean-Philippe ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - N0489
Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222 Mc Kean, Heidi , Stella, Philip J. , Hillman, Shauna L. ... - - Cancer Invest. - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - N0222
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database McCleary, Nadine J. , Meyerhardt, Jeffrey A. , Green, Erin ... - - J. Clin. Oncol - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Impact of smoking on patients with stage III colon cancer: Results from CALGB 89803 McCleary, Nadine Jackson , Niedzwiecki, Donna , Hollis, Donna ... - - Cancer - 2010 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803
Concordance of HER2 Central Assessment by Two International Central Laboratories: a ring study within the framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708. McCullough, AE , Dell'Orto, P , Reinholz, MM ,
